sunvozertinib
dizal pharmaceuticals
['sunvozertinib', 'dzd9008']
sunvozertinib dzd9008 in egfrex20ins phase 2 wukong6 (china only) post platinum. 32% cns mets. orr impressive 60.8%. responses with cns mets &amp; ami exposure. egfrwt toxicities. nice data and sets high bar for others to beat.1st line dzd vs chemo ongoing. #asco23 
Thoracic Oncologist @royalmarsdenNHS, Professor @ICR_London; Chair @BTOGorg; views are my own.